Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

Haematologica

Volumn 97, Issue 4, 2012, Pages 543-550

  Cristóbal, Ion ^a,b   Garcia Orti, Laura ^a   Cirauqui, Cristina ^a   Cortes Lavaud, Xabier ^a   García Sánchez, María A ^a   Calasanz, María J ^b   Odero, María D ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Acute leukemia; PP2A; Prognostic factor; SET

Indexed keywords

ANTHRACYCLINE; CASPASE 3; CASPASE 7; CYTARABINE; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; SET PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; OVERALL SURVIVAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE CHAPERONES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN PHOSPHATASE 2; RECURRENCE; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84859449771     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.050542     Document Type: Article

References (29)

1. Fathi AT, Grant S,Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev. 2010;36(2):142-150.
2. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271(19):11059-11062.
3. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001;104(1): 119-130.
4. Kutney SN, Hong R, Macfarlan T, Chakravarti D. A signaling role of histonebinding proteins and INHAT subunits pp32 and Set/TAF-Ibeta in integrating chromatin hypoacetylation and transcriptional repression. J Biol Chem. 2004; 279(29):30850-30855.
5. Kandilci A, Mientjes E, Grosveld G. Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. Leukemia. 2004; 18(2):337-340.
6. ten Klooster JP, Leeuwen I, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. Embo J. 2007;26(2):336-345.
7. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, et al. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem. 2003;278(2):1158-1164.
8. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14(4):152-160.
9. Trotta R, Ciarlariello D, Dal Col J, Allard J 2nd, Neviani P, Santhanam R, et al. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med. 2007;204(10):2397-2405.
10. Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, et al. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood. 2011;117(8):2378-2384.
11. Al-Murrani SW, Woodgett JR, Damuni Z. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J. 1999;341(Pt 2):293-298.
12. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTLmediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003;112(5):659-672.
13. Harmala-Brasken AS, Mikhailov A, Soderstrom TS, Meinander A, Holmstrom TH, Damuni Z, et al. Type-2A protein phosphatase activity is required to maintain death receptor responsiveness. Oncogene. 2003;22(48):7677-7686.
14. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002; 277(28):25026-25031.
15. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-368.
16. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Aktmediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004;18(8): 912-925.
17. Kawabe T, Muslin AJ, Korsmeyer SJ. HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cellcycle checkpoint. Nature. 1997;385(6615):454-458.
18. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130(1):21-24.
19. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353 (Pt 3):417-439.
20. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15(1):34-41.
21. Schonthal AH. Role of serine/threonine proteinphosphatase 2A in cancer. Cancer Lett. 2001;170(1):1-13.
22. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-2421.
23. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008;111(1): 275-284.
24. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010;115(3):615-625.
25. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011;25(4):606-614.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
27. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ, et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett. 2010;291(1):99-107.
28. Farag SS, Ruppert AS, Mrozek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(3):482-493.
29. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30(22):2504-2513.